MA30142B1 - Agonistes du recepteur de neuropeptide-2 - Google Patents

Agonistes du recepteur de neuropeptide-2

Info

Publication number
MA30142B1
MA30142B1 MA31085A MA31085A MA30142B1 MA 30142 B1 MA30142 B1 MA 30142B1 MA 31085 A MA31085 A MA 31085A MA 31085 A MA31085 A MA 31085A MA 30142 B1 MA30142 B1 MA 30142B1
Authority
MA
Morocco
Prior art keywords
neuropeptide
receptor agonists
obesity
diabetes
moieties
Prior art date
Application number
MA31085A
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
George Ehrlich
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Rebecca Anne Taub
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30142(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30142B1 publication Critical patent/MA30142B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Agonistes du récepteur de neuropeptide-2 Il est proposé dans le présent mémoire des agonistes du récepteur de neuropeptide-2, de formule (I), Y¿ I Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2 (I) ainsi que leurs sels, dérivés et fragments pharmaceutiquement acceptables, formule dans laquelle les substituants sont ceux décrits dans le présent mémoire. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies telles que, par exemple, l'obésité et le diabète.
MA31085A 2005-12-07 2008-07-01 Agonistes du recepteur de neuropeptide-2 MA30142B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30

Publications (1)

Publication Number Publication Date
MA30142B1 true MA30142B1 (fr) 2009-01-02

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31085A MA30142B1 (fr) 2005-12-07 2008-07-01 Agonistes du recepteur de neuropeptide-2

Country Status (18)

Country Link
US (2) US7642244B2 (fr)
EP (1) EP1962959B1 (fr)
JP (1) JP5000663B2 (fr)
KR (1) KR101059602B1 (fr)
AR (1) AR057222A1 (fr)
AT (1) ATE549350T1 (fr)
AU (1) AU2006324076A1 (fr)
BR (1) BRPI0619573A2 (fr)
CA (1) CA2630649A1 (fr)
EC (1) ECSP088511A (fr)
ES (1) ES2381497T3 (fr)
IL (1) IL191636A (fr)
MA (1) MA30142B1 (fr)
NO (1) NO20082445L (fr)
NZ (1) NZ568772A (fr)
RU (2) RU2430108C2 (fr)
TW (1) TWI321474B (fr)
WO (1) WO2007065808A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
WO2007065808A2 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CN102202681A (zh) * 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (fr) * 2009-09-18 2012-07-25 Novo Nordisk A/S Agonistes du récepteur y2 à action prolongée
WO2011045232A2 (fr) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2 (y-2r)
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CA2822481A1 (fr) * 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag Composition pharmaceutique a base d'un complexe associant un anticorps anti-dig et de la digoxigenine conjuguee a un peptide
EP4324475A1 (fr) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions de peptides glp-1 et leur préparation
JP6324376B2 (ja) 2012-07-04 2018-05-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗テオフィリン抗体および使用方法
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
BR112014030844A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
EP3089758B1 (fr) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Conjugués d'anticorps helicar-anti-helicar liés par covalence et leurs utilisations
EP3089759B1 (fr) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Conjugués covalents entre un anticorps et une toxine polypeptidique
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2988500A1 (fr) 2015-06-12 2016-12-15 Novo Nordisk A/S Composes pyy selectifs et leurs utilisations
WO2019149880A1 (fr) 2018-02-02 2019-08-08 Novo Nordisk A/S Compositions solides comprenant un agoniste de glp -1 et un sel d'acide n- (8- (2-hydroxybenzoyl) amino) caprylique
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
EP0692971A4 (fr) * 1993-03-29 1997-11-12 Univ Cincinnati Analogues du peptide yy et leurs utilisations
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
EP1583549A4 (fr) 2003-01-17 2006-10-04 Sod Conseils Rech Applic Analogues du peptide yy
CA2521784C (fr) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
JP2007512365A (ja) 2003-11-25 2007-05-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 選択的神経ペプチドｙ２受容体作動薬
EP1718671A2 (fr) 2004-02-23 2006-11-08 Rheoscience A/S Analogues du peptide yy
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (fr) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Agonistes du recepteur y de neuropeptide
WO2007065808A2 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2
WO2007085887A1 (fr) 2006-01-27 2007-08-02 Pfizer Products Inc. Agonistes du pyy et leurs utilisations

Also Published As

Publication number Publication date
JP5000663B2 (ja) 2012-08-15
AU2006324076A1 (en) 2007-06-14
WO2007065808A2 (fr) 2007-06-14
KR101059602B1 (ko) 2011-08-25
AR057222A1 (es) 2007-11-21
US20070135351A1 (en) 2007-06-14
IL191636A0 (en) 2008-12-29
ES2381497T3 (es) 2012-05-28
IL191636A (en) 2012-10-31
CA2630649A1 (fr) 2007-06-14
EP1962959A2 (fr) 2008-09-03
EP1962959B1 (fr) 2012-03-14
NO20082445L (no) 2008-09-03
TWI321474B (en) 2010-03-11
TW200806311A (en) 2008-02-01
RU2008127265A (ru) 2010-01-20
ATE549350T1 (de) 2012-03-15
ECSP088511A (es) 2008-07-30
US8268784B2 (en) 2012-09-18
KR20080082672A (ko) 2008-09-11
US7642244B2 (en) 2010-01-05
BRPI0619573A2 (pt) 2011-10-04
NZ568772A (en) 2010-05-28
RU2011105310A (ru) 2012-08-20
US20100137223A1 (en) 2010-06-03
WO2007065808A3 (fr) 2007-08-02
JP2009518349A (ja) 2009-05-07
RU2430108C2 (ru) 2011-09-27

Similar Documents

Publication Publication Date Title
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
Barbey et al. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor
MA29926B1 (fr) Derives de pyrazine
MA28747B1 (fr) Dérivés de pyridine
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA31754B1 (fr) Cis-imidazolines chirales
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
TN2009000450A1 (fr) Derives de pyridine
MA31766B1 (fr) Composés organiques
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA29909B1 (fr) Derives de pyridazine
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament